Opus Genetics (IRD) Common Equity (2010 - 2026)

Opus Genetics (IRD) has 17 years of Common Equity data on file, last reported at -$45.8 million in Q1 2026.

• Quarterly Common Equity fell 1003.53% year-over-year to -$45.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.8 million (down 1003.53% YoY) and the FY2025 annual result came in at $15.3 million, up 128.26% from the prior year.
• Common Equity declined to -$45.8 million in Q1 2026 per IRD's latest filing, from $15.3 million in the prior quarter.
• Across five years, Common Equity topped out at $50.3 million in Q3 2023 and bottomed at -$45.8 million in Q1 2026.
• The 5-year median for Common Equity is $17.5 million (2025), against an average of $23.2 million.
• The widest annual swing landed in 2023, when Common Equity soared 323.36%; it then slumped 1003.53% in 2026.
• Tracing IRD's Common Equity over 5 years: stood at $46.2 million in 2022, then rose by 7.93% to $49.9 million in 2023, then slumped by 86.53% to $6.7 million in 2024, then jumped by 128.26% to $15.3 million in 2025, then plunged by 398.64% to -$45.8 million in 2026.
• Per Business Quant, the three latest IRD Common Equity figures stand at -$45.8 million (Q1 2026), $15.3 million (Q4 2025), and $6.0 million (Q3 2025).

Peer Comparison